Health Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo, after Australian TGA clearances
Health Canada approved Eli Lilly’s oral GLP-1 medication Foundayo for obesity and weight-related health issues. The approval follows earlier clearances by Australia’s Therapeutic Goods Administration, which had already authorized the daily tablet for adults with type 2 diabetes and obesity, providing a new oral option alongside existing injectable treatments. The Therapeutic Goods Administration’s decisions were reported by multiple Australian health outlets, noting that Foundayo joins Novo Nordisk’s Wegovy tablet as a prescription-only GLP-1 therapy available to patients later in the year.